耐药基因在胃癌中表达及其临床应用

Expression or drug-resistance gene protein in gastric cancer and clinical applications

目的探讨胸苷酸全成酶(TS)、谷胱甘肽-S-转移酶Pi(GST-Pi)、拓普异构酶Ⅱa(TOPOⅡ)和Ki-67在胃癌中的表达以指导临床化疗。方法应用LDP免疫组化法检测胃癌中耐药基因蛋白的表达,做药物适配分析和临床病理参数相关性分析。结果 TS、GST-Pi、TOPOⅡ和Ki-67的阳性表达率分别是49%、90%、100%。半定量TS(35±17)%,GST-Pi(65±18)%,TOPOⅡ(50±14)%,Ki-67(60±14)%。有96%的患者对两类药物适配细胞比例之和≥110%。阳性表达率和半定量在临床分期、肿瘤分化程度和有无淋巴结转移之间差异无统计学意义。结论组合检测TS、GST-pi、TOPOⅡ、Ki-67的表达和药物适配分析能为胃癌患者提供"个体化"化疗数据,达到最佳药物适配,逆转耐高表达者的不良预后。

Objective To investigate the expression of thymidylate synthase（TS）,Glutaione S-Transferase Pi（GST-Pi）,TopoisomeraseⅡa（TOPOⅡ） and Ki-67 in gastric cancer for guiding clinical chemotherapy.Methods Used of immunohistochemical dye,in order to detect the expression of drug-resistance gene protein in gastric cancer,and did relativity analysis between the pharmaceutical fitting,and clinical pathological parameter.Results The positive rate of expression of TS,GST-Pi,TOPOⅡ and Ki-67 was respectively 49%,90%,100% in 81 cases of gastric cancer.Their half-quantity TS was（35±17）%,GST-pi（65±18）%,TOPOI（50±14）%,Ki-67（60±14）%.There are 96% cases whose summation of percent rate of 2 Kinds of pharmaceurtical fitting cell that was more than 110%.Their positive rate and the intensity difference didn＇t statistical signfficance between the clinical staging,and the degree of differentiation,and did or no metastasis cancer.Conclusion It can provide the data for the chemotherapy of gastric cancer cases that can get to optimal Pharmaceutical fitting by combined detect expression of TS,GST-Pi,TOPOⅡand Ki-67,high-cxpresser of drug-resistance gene will can revrse their ill prognoses if choose else kinds of sensitive drug.